Where Nordic Science Meets Global Scale

BSP Pharmaceuticals is a CDMO, technologically developed to meet needs of groundbreakers and specialized in manufacturing Oncology and Immunotherapy drug, including autoimmune disease, immunotherapy & CNS among others, with a strategic interest in specific therapeutic areas.

In a campus of  approximately 60 acres, with approximately 650,000 sqf built surface,  the facility is designed to handle conventional small molecules, Biologics and ADCs (from Conjugation to Fill Finish) and very much focused on innovative compounds.

With full containment facility, applying the most advanced and safe technologies, BSP can offer a wide range of services for Pre-Clinical, Clinical and Commercial supply in compliance with the highest Quality requirements.

BSP is positioned as a centre of excellence and a valued strategic partner among those small and large pharma and biotech companies with an advanced outsourcing process for strategic products with a high technological content.

Cytiva and Pall Life Sciences have come together to deliver the breadth, depth, and scale researchers and biopharma need to advance future therapeutics—from discovery to delivery. Together, as Cytiva, we supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such asAllegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™.

Kemwell Biopharma is a leading biologics Contract Development and Manufacturing Organization (CDMO) based in Bengaluru, India, offering end-to-end services from cell line and process development to cGMP clinical and commercial manufacturing.

Its 15,000 sq. m facility, designed in collaboration with Boehringer Ingelheim, includes process development, analytical, and formulation laboratories, as well as drug-substance manufacturing (over 5,000 L bioreactor capacity) and sterile fill-finish for vials and prefilled syringes (PFS).

In 2025, Kemwell successfully completed a U.S. FDA Pre-Approval Inspection (PAI) for an injectable drug product for the U.S. market, highlighting its global regulatory compliance and quality excellence.

Established in 1980, Kemwell partners with leading pharma companies worldwide to deliver cost-effective, high-quality biologics manufacturing solutions.

Pharma at Brenntag is more than you think. From specialty ingredients distribution to GMP manufacturing and services, Brenntag Pharma is the trusted advisor to the biopharmaceutical and pharmaceutical industry. With a dedicated team of industry experts, it creates value for their global business partners through customized buffer solutions and repackaging under GMP conditions, warehousing in GDP sites, regulatory support, analytical services and more. Brenntag Pharma serves various markets, including Biopharma, APIs, Excipients, Regulated Synthesis and Nutritional Health.

Cobetter is a technology driven company specializing in advanced filtration, separation, and fluid management solutions. With a diversified business footprint spanning biopharmaceuticals, semiconductors, new energy, and industrial manufacturing, the company combines deep expertise in membrane materials, process engineering, and precision manufacturing to support critical and highly regulated applications worldwide.

In the biopharmaceutical sector, Cobetter offers a comprehensive and integrated portfolio designed to support the full bioprocess workflow, from upstream to downstream and final fill. The bioprocess product offering includes single-use bags and assemblies, virus removal membrane cassettes, ultrafiltration membrane cassettes for concentration and buffer exchange, sterile filtration cartridges, and membrane chromatography products for polishing and impurity removal. Together, these solutions enable flexible, scalable, and efficient biomanufacturing processes.

Leveraging proprietary membrane technologies and robust quality systems, Cobetter develops products that meet the demanding requirements of biologics production, including monoclonal antibodies, vaccines, and other advanced therapeutic modalities. The company works closely with biopharmaceutical manufacturers, CDMOs, and research institutions to provide application-oriented support, from early-stage process development to commercial-scale manufacturing.

Driven by a commitment to quality, innovation, and long-term customer partnership, Cobetter continues to expand its bioprocessing platform and global service capabilities. Through continuous technology development and close collaboration with customers, the company helps accelerate development timelines, improve process robustness, and enable reliable, compliant biopharmaceutical manufacturing.

‍